Biogen Idec Inc (BIIB) 285.92 $BIIB
Stocks Rally, Stall, Turn Mixed; Consol Energy, U.S. Steel Jump
at Investor's Business Daily - Tue Apr 08, 9:29AM CDT
Early gains quickly flickered into a mixed performance Tuesday, with China-based stocks grabbing a large share of early gains. The Nasdaq bobbed to a 0.2% gain. The S&P 500 eased 0.1%. The Dow Jones industrial average dipped 0.2%. Volume was mixed,...
Earnings Release Schedules, Product Portfolio Expansion, Initiatives and Stock Price Movements - Analyst Notes on Biogen Idec, Bristol-Myers, Regeneron Pharma, Illumina, West Pharma Services
PR Newswire - Tue Apr 08, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), Bristol-Myers Squibb Company (NYSE: BMY), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Illumina Inc. (NASDAQ: ILMN), and West Pharmaceutical Services, Inc. (NYSE: WST). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Tweet of the Week: Big Biotech Dominates Industry Gains
Brian Orelli and Max Macaluso, The Motley Fool - Motley Fool - Mon Apr 07, 4:25PM CDT
This week's tweet comes from Bruce Booth (@LifeSciVC), who points out analysts at Bernstein concluded that just six companies contributed to 77% of the increase in value of the biotech sector over the past three years. There's no doubt that Amgen...
Biogen Idec May Have Seeds For Next-Gen MS Drugs
at Investor's Business Daily - Mon Apr 07, 3:51PM CDT
Biogen Idec (BIIB), on the IBD 50 list of top-rated growth stocks, is working on a new oral drug for treating multiple sclerosis that has the potential for driving the biotech firm's next generation of MS therapies, according to a research note from...
Stocks Weaken In Late Trade; Questcor Pares Gains
at Investor's Business Daily - Mon Apr 07, 1:57PM CDT
Stocks continued to worsen in late trading Monday and were on pace for a third straight loss. The Nasdaq slumped 1.7% to a two-month low. The S&P 500 dropped 1.2%, putting it near its 50-day line. Meanwhile, the Dow Jones industrial average lost 1%....
Does Biogen Idec Inc Have a New Blockbuster Hemophilia Therapy?
Cory Renauer, The Motley Fool - Motley Fool - Mon Apr 07, 1:30PM CDT
The FDA recently approved Biogen Idec 's Alprolix for the treatment of hemophilia B. The longer-lasting therapy's convenient dosing requirements may help it quickly dig into Pfizer 's BeneFIX market share. The Alprolix marketing team better...
Momentum Slide to Continue for Netflix, Facebook? - Analyst Blog
Swarup Gupta - Zacks Investment Research - Mon Apr 07, 12:21PM CDT
Momentum stocks may soon bounce back, but for now earnings hold the key.
Major Averages Face More Selling, Biotechs Rally Back
at Investor's Business Daily - Mon Apr 07, 11:01AM CDT
Stocks were under pressure and near session lows about two hours into Monday's session. Biotechs bucked the trend, rallying back after recent weakness. The Dow Jones industrial average lost 0.6%, while the Nasdaq and S&P 500 fell 0.5%. Nasdaq volume...
IBD 50 Stocks Fade With Market; Some Trip Sell Rules
at Investor's Business Daily - Fri Apr 04, 5:28PM CDT
A number of IBD 50 stocks are flashing warning signals amid the market's renewed sell-off. Facebook (FB) reversed lower this past week and fell 5% in heavy volume. The stock has fallen for four straight weeks, piercing its 10-week moving average and...
Stock Market News for April 04, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 9:06AM CDT
Benchmarks snapped a four-day winning streak and ended lower on Thursday as investors adopted a wait and watch approach ahead of Friday’s nonfarm payroll data
Stocks Fall Ahead Of Jobs Data; Palo Alto, Tableau Slide
at Investor's Business Daily - Thu Apr 03, 4:31PM CDT
Stocks put in a downside reversal Thursday ahead of Friday's key jobs report, which is expected to show an increase of 206,000 new jobs during March, according to Econoday. Hurt by Internet, software and biotech stocks, the Nasdaq tumbled 0.9%. The...
Drugmakers Build to Buy
Brian Orelli, The Motley Fool - Motley Fool - Thu Apr 03, 4:15PM CDT
If you build it, they will buy it (especially if they told you what to build to begin with). Quite a few big biotechs and pharmaceutical companies have called on venture capital firms to help them develop companies and compounds that they can...
Nasdaq Sheds 1% As China Growth Names, Biotechs Fall Hard
at Investor's Business Daily - Thu Apr 03, 1:53PM CDT
The Dow Jones industrial average and S&P 500 didn't move much Thursday, but it was a different story on the Nasdaq as growth stocks -- biotechs in particular -- took heavy hits. With a little over one hour remaining in the session, the Nasdaq lost...
S&P 500 Edges Lower As Biotech Selling Weighs On Nasdaq
at Investor's Business Daily - Thu Apr 03, 12:27PM CDT
Stocks were lower early Thursday afternoon as biotechs faced a fresh barrage of selling ahead of Friday's jobs report. Selling pressure was muted in the S&P 500 and the Dow, but it was a different story on the Nasdaq. The tech-heavy index lost 1%,...
Insider Trading Alert - DVA, ACN And BIIB Traded By Insiders
at The Street - Thu Apr 03, 9:31AM CDT
Stocks with insider trader activity include DVA, ACN and BIIB
Will Biogen Idec Inc. Rule Biotech in 2014?
Dan Carroll, The Motley Fool - Motley Fool - Thu Apr 03, 8:30AM CDT
The biotech sector's endured an up-and-down 2014 after the immense gains captured in 2013's market rise, but don't tell that to fast-rising Biogen Idec . Biogen's stock has roared higher by more than 10% in 2014 after experiencing a tremendous...
Tradable Biotech Stocks Events For the Second Quarter
at The Street - Thu Apr 03, 8:00AM CDT
The biotech sector's March "fluctuation" might be a temporary speed bump or the beginning of a longer downturn. Either way, investors can still count on the biotech catalyst trade for chills and thrills.
Bioprinting Investment Puts RBCC at Forefront of 3-D Revolution
Business Wire - Thu Apr 03, 4:00AM CDT
By substantially increasing its investment in biotech innovators Nano3D Biosciences, Rainbow Coral Corp. (OTCBB: RBCC) has positioned itself on the front lines of a bioprinting revolution poised to forever alter the possibilities of healthcare.
Biotech Stock Roundup: Biogen Drug Approved, Exelixis Tumbles on Study Update - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 02, 9:43AM CDT
Biotech companies continued to witness a decline in share prices last week.
Insider Trading Alert - CRM, BIIB And CDNS Traded By Insiders
at The Street - Wed Apr 02, 9:30AM CDT
Stocks with insider trader activity include CRM, BIIB and CDNS
Stocks Rally, Stall, Turn Mixed; Consol Energy, U.S. Steel Jump
at Investor's Business Daily - Tue Apr 08, 9:29AM CDT
Early gains quickly flickered into a mixed performance Tuesday, with China-based stocks grabbing a large share of early gains. The Nasdaq bobbed to a 0.2% gain. The S&P 500 eased 0.1%. The Dow Jones industrial average dipped 0.2%. Volume was mixed,...
Earnings Release Schedules, Product Portfolio Expansion, Initiatives and Stock Price Movements - Analyst Notes on Biogen Idec, Bristol-Myers, Regeneron Pharma, Illumina, West Pharma Services
PR Newswire - Tue Apr 08, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), Bristol-Myers Squibb Company (NYSE: BMY), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Illumina Inc. (NASDAQ: ILMN), and West Pharmaceutical Services, Inc. (NYSE: WST). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Tweet of the Week: Big Biotech Dominates Industry Gains
Brian Orelli and Max Macaluso, The Motley Fool - Motley Fool - Mon Apr 07, 4:25PM CDT
This week's tweet comes from Bruce Booth (@LifeSciVC), who points out analysts at Bernstein concluded that just six companies contributed to 77% of the increase in value of the biotech sector over the past three years. There's no doubt that Amgen...
Biogen Idec May Have Seeds For Next-Gen MS Drugs
at Investor's Business Daily - Mon Apr 07, 3:51PM CDT
Biogen Idec (BIIB), on the IBD 50 list of top-rated growth stocks, is working on a new oral drug for treating multiple sclerosis that has the potential for driving the biotech firm's next generation of MS therapies, according to a research note from...
Stocks Weaken In Late Trade; Questcor Pares Gains
at Investor's Business Daily - Mon Apr 07, 1:57PM CDT
Stocks continued to worsen in late trading Monday and were on pace for a third straight loss. The Nasdaq slumped 1.7% to a two-month low. The S&P 500 dropped 1.2%, putting it near its 50-day line. Meanwhile, the Dow Jones industrial average lost 1%....
Does Biogen Idec Inc Have a New Blockbuster Hemophilia Therapy?
Cory Renauer, The Motley Fool - Motley Fool - Mon Apr 07, 1:30PM CDT
The FDA recently approved Biogen Idec 's Alprolix for the treatment of hemophilia B. The longer-lasting therapy's convenient dosing requirements may help it quickly dig into Pfizer 's BeneFIX market share. The Alprolix marketing team better...
Momentum Slide to Continue for Netflix, Facebook? - Analyst Blog
Swarup Gupta - Zacks Investment Research - Mon Apr 07, 12:21PM CDT
Momentum stocks may soon bounce back, but for now earnings hold the key.
Major Averages Face More Selling, Biotechs Rally Back
at Investor's Business Daily - Mon Apr 07, 11:01AM CDT
Stocks were under pressure and near session lows about two hours into Monday's session. Biotechs bucked the trend, rallying back after recent weakness. The Dow Jones industrial average lost 0.6%, while the Nasdaq and S&P 500 fell 0.5%. Nasdaq volume...
IBD 50 Stocks Fade With Market; Some Trip Sell Rules
at Investor's Business Daily - Fri Apr 04, 5:28PM CDT
A number of IBD 50 stocks are flashing warning signals amid the market's renewed sell-off. Facebook (FB) reversed lower this past week and fell 5% in heavy volume. The stock has fallen for four straight weeks, piercing its 10-week moving average and...
Stock Market News for April 04, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 9:06AM CDT
Benchmarks snapped a four-day winning streak and ended lower on Thursday as investors adopted a wait and watch approach ahead of Friday’s nonfarm payroll data
Stocks Fall Ahead Of Jobs Data; Palo Alto, Tableau Slide
at Investor's Business Daily - Thu Apr 03, 4:31PM CDT
Stocks put in a downside reversal Thursday ahead of Friday's key jobs report, which is expected to show an increase of 206,000 new jobs during March, according to Econoday. Hurt by Internet, software and biotech stocks, the Nasdaq tumbled 0.9%. The...
Drugmakers Build to Buy
Brian Orelli, The Motley Fool - Motley Fool - Thu Apr 03, 4:15PM CDT
If you build it, they will buy it (especially if they told you what to build to begin with). Quite a few big biotechs and pharmaceutical companies have called on venture capital firms to help them develop companies and compounds that they can...
Nasdaq Sheds 1% As China Growth Names, Biotechs Fall Hard
at Investor's Business Daily - Thu Apr 03, 1:53PM CDT
The Dow Jones industrial average and S&P 500 didn't move much Thursday, but it was a different story on the Nasdaq as growth stocks -- biotechs in particular -- took heavy hits. With a little over one hour remaining in the session, the Nasdaq lost...
S&P 500 Edges Lower As Biotech Selling Weighs On Nasdaq
at Investor's Business Daily - Thu Apr 03, 12:27PM CDT
Stocks were lower early Thursday afternoon as biotechs faced a fresh barrage of selling ahead of Friday's jobs report. Selling pressure was muted in the S&P 500 and the Dow, but it was a different story on the Nasdaq. The tech-heavy index lost 1%,...
Insider Trading Alert - DVA, ACN And BIIB Traded By Insiders
at The Street - Thu Apr 03, 9:31AM CDT
Stocks with insider trader activity include DVA, ACN and BIIB
Will Biogen Idec Inc. Rule Biotech in 2014?
Dan Carroll, The Motley Fool - Motley Fool - Thu Apr 03, 8:30AM CDT
The biotech sector's endured an up-and-down 2014 after the immense gains captured in 2013's market rise, but don't tell that to fast-rising Biogen Idec . Biogen's stock has roared higher by more than 10% in 2014 after experiencing a tremendous...
Tradable Biotech Stocks Events For the Second Quarter
at The Street - Thu Apr 03, 8:00AM CDT
The biotech sector's March "fluctuation" might be a temporary speed bump or the beginning of a longer downturn. Either way, investors can still count on the biotech catalyst trade for chills and thrills.
Bioprinting Investment Puts RBCC at Forefront of 3-D Revolution
Business Wire - Thu Apr 03, 4:00AM CDT
By substantially increasing its investment in biotech innovators Nano3D Biosciences, Rainbow Coral Corp. (OTCBB: RBCC) has positioned itself on the front lines of a bioprinting revolution poised to forever alter the possibilities of healthcare.
Biotech Stock Roundup: Biogen Drug Approved, Exelixis Tumbles on Study Update - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 02, 9:43AM CDT
Biotech companies continued to witness a decline in share prices last week.
Insider Trading Alert - CRM, BIIB And CDNS Traded By Insiders
at The Street - Wed Apr 02, 9:30AM CDT
Stocks with insider trader activity include CRM, BIIB and CDNS
